References
- 1. R. S. Geha and E. O. Meltzer, Desloratadine: a new, nonsedating, oral antihistamine, J. Allergy Clin. Immunol.107 (2001) 751–762; https://doi.org/10.1067/mai.2001.11423910.1067/mai.2001.114239
- 2. M. Molimard, B. Diquet and M.S. Benedetti, Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans, Fundam. Clin. Pharmacol.18 (2004) 399–411; https://doi.org/10.1111/j.1472-8206.2004.00254.x10.1111/j.1472-8206.2004.00254.x
- 3. J. Bartra, A. L. Valero, A. del Cuvillo, I. Dávila, I. Jáuregui, J. Montoro, J. Mullol and J. Sastre, Interactions of the H1 antihistamines, J. Investig. Allergol. Clin. Immunol. 16 (2006) 29–36.
- 4. R. Bustami, S. Khasawneh, W. Absi, H. Feddah, M. Menassa, E. Daccache, M. S. Taha and S. Kyriacos, Bioequivalence of a fixed dose combination of desloratadine/betamethasone tablets (Oradus Beta) in healthy human volunteers, J. Bioequiv. Availab.8 (2016) 233–241; doi:10.4172/jbb.100030110.4172/jbb.1000301
- 5. Prescriber Digital Reference (PDR), desloratadine – Drug Summary;http://www.pdr.net/drug-summary/Clarinex-desloratadine-334.789; access date March 19, 2018.
- 6. A. Crowe and C. Wright, The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers, Xenobiotica42 (2012) 538–549; https://doi.org/10.3109/00498254.2011.64325610.3109/00498254.2011.643256
- 7. B. R. Falcão, L. de Melo Teixeira, F. Z. Philippsen and T. R. Sausen, Development and validation of a dissolution method for desloratadine coated tablets, UK. J. Pharm. Biosci. 5 (2017) 12–17; http://dx.doi.org/10.20510/ukjpb/5/i1/14702010.20510/ukjpb/5/i1/147020
- 8. Erratum, Br. J. Clin. Pharmacol.74 (2012) 224–225; https://doi.org/10.1111/j.1365-2125.2012.04349.x10.1111/j.1365-2125.2012.04349.x
- 9. CDER/FDA, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for industry. 2017; https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf; access date March 19, 2018.
- 10. B. M. Davit, I. Kanfer, Y. C. Tsang and J. M. Cardot, BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements, AAPS J. 18 (2016) 612–618; https://doi.org/10.1208/s12248-016-9877-210.1208/s12248-016-9877-2
- 11. Bayer Inc., Product monograph Aerius®Desloratadine Tablet 5 mg Aerius Kids®Desloratadine syrup 0.5 mg/mL Histamine H1-Receptor Antagonist, November 2017; http://omr.bayer.ca/omr/online/aeriusaeriuskids-pm-en.pdf; access date March 19, 2018.
- 12. B. B. Hodgson and R. J. Kizior, Desloratadine, in Saunders nursing drug handbook, Elsevier/Saunders, St. Louis 2012, pp. 326–328.
- 13. R. Ramanathan, L. Reyderman, A. D. Su, N. Alvarez, S. K. Chowdhury, K. B. Alton, M. A. Wirth, R. P. Clement, P. Statkevich and J. E. Patrick, Disposition of desloratadine in healthy volunteers, Xenobiotica37 (2007) 770–787; https://doi.org/10.1080/0049825070146332510.1080/00498250701463325
- 14. G. Popović, M. Čakar and D. Agbaba, Acid–base equilibria and solubility of loratadine and desloratadine in water and micellar media, J. Pharm. Biomed. Anal.49 (2009) 42–47; https://doi.org/10.1016/j.jpba.2008.09.04310.1016/j.jpba.2008.09.043
- 15. T. C. McIlvaine, A buffer solution for colorimetric comparison, J. Biol. Chem.49 (1921) 183–186.10.1016/S0021-9258(18)86000-8
- 16. S. Žakelj, K. Šturm and A. Kristl, Ciprofloxacin permeability and its active secretion through rat small intestine in vitro, Int. J. Pharm.313 (2006) 175–180; https://doi.org/10.1016/j.ijpharm.2006.02.00410.1016/j.ijpharm.2006.02.00416529884
- 17. L. Peternel, K. Kristan, M. Petruševska, T. L. Rižner and I. Legen, Suitability of isolated rat jejunum model for demonstration of complete absorption in humans for BCS-based biowaiver request, J. Pharm. Sci.101 (2012) 1436–1449; https://doi.org/10.1002/jps.2302710.1002/jps.2302722234826
- 18. T. Wang, K. Zhang, T. Li, L. He, H. Xie, X. Jiang and L. Wang, Prevalence of desloratadine slow-metabolizer phenotype and food-dependent pharmacokinetics of desloratadine in healthy Chinese volunteers, Clin. Drug. Investig.35 (2015) 807–813; https://doi.org/10.1007/s40261-015-0343-110.1007/s40261-015-0343-126446005
- 19. M. Zur, M. Gasparini, O. Wolk, G. L. Amidon and A. Dahan, The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol, Mol. Pharm. 11 (2014) 1707–1714; https://doi.org/10.1021/mp500152y10.1021/mp500152y24735251
- 20. D. A. Volpe, Application of method suitability for drug permeability classification, The AAPS J.12 (2010) 670–678; https://doi.org/10.1208/s12248-010-9227-810.1208/s12248-010-9227-8297698420811966
- 21. T. Jarc, M. Novak, N. Hevir, T. Lanišnik Rižner, M. Erdani Kreft and K. Kristan, Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines, J. Pharm. Pharmacol. (2019), article in press.10.1111/jphp.1311131155721
- 22. C. A. Larregieu and L. Z. Benet, Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery, Mol. Pharm.11 (2014) 1335–1344; https://doi.org/10.1021/mp400785810.1021/mp4007858398336924628254
- 23. S. Ferruzza, C. Rossi, M. L. Scarino and Y. Sambuy, A protocol for differentiation of human intestinal Caco-2 cells in asymmetric serum-containing medium, Toxicol. In Vitro26 (2012) 1252–1255; https://doi.org/10.1016/j.tiv.2012.01.00810.1016/j.tiv.2012.01.00822265977